Natriuretic peptides in cardiometabolic regulation and disease

被引:138
|
作者
Zois, Nora E. [1 ]
Bartels, Emil D. [1 ]
Hunter, Ingrid [1 ]
Kousholt, Birgitte S. [2 ]
Olsen, Lisbeth H. [3 ]
Goetze, Jens P. [1 ]
机构
[1] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[2] Aarhus Univ, Fac Hlth Sci, Dept Clin Med, DK-8200 Aarhus, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet Dis Biol, DK-1870 Copenhagen, Denmark
关键词
BROWN ADIPOSE-TISSUE; STIMULATED PHOSPHOPROTEIN VASP; LIMITS INFARCT SIZE; HIGH BLOOD-PRESSURE; B-TYPE; MICE LACKING; NITRIC-OXIDE; RECEPTOR-C; MYOCARDIAL-INFARCTION; CARDIAC-HYPERTROPHY;
D O I
10.1038/nrcardio.2014.64
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the 30 years since the identification of the natriuretic peptides, their involvement in regulating fluid and blood pressure has become firmly established. Data indicating a role for these hormones in lifestyle-related metabolic and cardiovascular disorders have also accumulated over the past decade. Dysregulation of the natriuretic peptide system has been associated with obesity, glucose intolerance, type 2 diabetes mellitus, and essential hypertension. Moreover, the natriuretic peptides have been implicated in the protection against atherosclerosis, thrombosis, and myocardial ischaemia. All these conditions can coexist and potentially lead to heart failure, a syndrome associated with a functional natriuretic peptide deficiency despite high circulating concentrations of immunoreactive peptides. Therefore, dysregulation of the natriuretic peptide system, a 'natriuretic handicap', might be an important factor in the initiation and progression of metabolic dysfunction and its accompanying cardiovascular complications. This Review provides a summary of the natriuretic peptide system and its involvement in these cardionnetabolic conditions. We propose that these peptides might have an integrating role in lifestyle-related metabolic and cardiovascular disorders.
引用
收藏
页码:403 / 412
页数:10
相关论文
共 50 条
  • [41] Natriuretic Peptides as Markers of Cardiovascular Risk: The Story Continues
    Ventura, Hector O.
    Silver, Marc A.
    MAYO CLINIC PROCEEDINGS, 2011, 86 (12) : 1143 - 1145
  • [42] ATRIAL AND BRAIN NATRIURETIC PEPTIDES IN CARDIOVASCULAR-DISEASES
    NARUSE, M
    TAKEYAMA, Y
    TANABE, A
    HIROSHIGE, J
    NARUSE, K
    YOSHIMOTO, T
    TANAKA, M
    KATAGIRI, T
    DEMURA, H
    HYPERTENSION, 1994, 23 (01) : I231 - I234
  • [43] Natriuretic peptides:: Biomarkers not predictive in the intensive care unit
    Ginsberg, Fredric
    Topalian, Simon
    CRITICAL CARE MEDICINE, 2007, 35 (04) : 1194 - 1195
  • [44] Natriuretic peptides in the control of lipid metabolism and insulin sensitivity
    Verboven, K.
    Hansen, D.
    Jocken, J. W. E.
    Blaak, E. E.
    OBESITY REVIEWS, 2017, 18 (11) : 1243 - 1259
  • [45] Molecular biology of natriuretic peptides and nitric oxide synthases
    Kone, BC
    CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 429 - 441
  • [46] Natriuretic peptides in cardiovascular diseases: current use and perspectives
    Volpe, Massimo
    Rubattu, Speranza
    Burnett, John, Jr.
    EUROPEAN HEART JOURNAL, 2014, 35 (07) : 419 - +
  • [47] Natriuretic peptides and cGMP signaling control of energy homeostasis
    Moro, Cedric
    Lafontan, Max
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2013, 304 (03): : H358 - H368
  • [48] Cardiometabolic Disorders in Psoriatic Disease
    Sobchak, Curtis
    Eder, Lihi
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (10)
  • [49] Role of natriuretic peptides in the assessment of aortic stenosis severity
    Davicevic, Zaklina
    Tavciovski, Dragan
    Matunovic, Radomir
    Vukotic, Snjezana
    Mijailovic, Zdravko
    VOJNOSANITETSKI PREGLED, 2010, 67 (08) : 622 - 626
  • [50] The incretin system and cardiometabolic disease
    Szmitko, Paul E.
    Leiter, Lawrence A.
    Verma, Subodh
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 (02) : 87 - 95